The U.S. general anesthesia drugs market is poised for rapid growth, according to a MarketsandMarkets report.
Here are seven key trends:
1. The market is expected to reach $2 billion by 2020.
2. It is currently valued at $1.6 billion.
3. The market is estimated to grow at a compound annual growth rate of 3.8 percent from 2015 to 2020.
4. Factors such as rapid rise in aging population and rising prevalence of cardiovascular and respiratory system-related diseases are driving the growth of the market.
5. But other factors such as side effects associated with ketamine usage and regulatory issues are likely to restrain the growth of this market.
6. The intravenous segment is expected to account for the largest share of the U.S. general anesthesia drugs market in 2015.
7. Major players operating in the market are AstraZeneca, Baxter International and Hikma Pharmaceuticals.